Therapy News and Research

RSS

Moderna provides an update on regulatory submissions for RSV vaccine candidate, mRNA-1345

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older.

10 Jul 2023

New study shows circulating anti-insulin CD4 T cells reflect progression of anti-islet immunity

In a recent study published in Science Translational Medicine, researchers profile antigen-specific helper clusters of differentiation 4-positive (CD4+) T-lymphocytes to determine anti-islet autoimmunity among mice and humans.

9 Jul 2023

Unique plant extract mixture has potent anti-acne effects

Researchers evaluate the efficacy of FRO, a formula composed of fermented Rhus verniciflua Stokes and Orostachys japonicus, against acne pathogenesis via antimicrobial assessment and an in vitro analysis. FRO was found to contain phenolics such as gallic acid, fisetin, quercetin, and kaempferol and was determined to alleviate acne by inhibiting the growth of Cutibacterium acnes, inflammation, and excess sebum.

9 Jul 2023

MTB offers precision oncology strategy for advanced cancer patients

The collaborative group led by the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed) and the Division of Clinical Pathology & Molecular Pathology, Hong Kong Sanatorium & Hospital (HKSH), have recently published their findings on the clinical importance of the Multidisciplinary Molecular Tumour Board (MTB) in delivering a Precision Cancer Medicine service.

7 Jul 2023

Novel approach sheds light on the interactions between SARS-CoV-2 viruses and human placenta

Until now, scientific evidence has been inconclusive regarding the ability of SARS-CoV-2, the virus that causes COVID, to replicate in the human placenta.

7 Jul 2023

Triple combination therapy shows promise in long-term treatment of cystic fibrosis

The mucus in the airways is not as sticky, inflammation in the lungs significantly reduced: Triple combination therapy can achieve these positive, lasting effects in patients with cystic fibrosis (CF).

7 Jul 2023

Researchers show how communication networks in the tumor microenvironment promote cancer growth

Tumors consist of both the actual, malignant cancer cells and healthy, non-transformed cells in the immediate environment.

7 Jul 2023

Medi-Cal’s fragmented system can make moving a nightmare

When Lloyd Tennison moved from Walnut Creek to Stockton last year, he assumed his coverage under Medi-Cal, California's safety-net health insurance program, would be transferred seamlessly.

7 Jul 2023

Healthy diet shown to lower cardiovascular disease risk in adult childhood cancer survivors

Research explores the impact of dietary patterns on the risk of cardiovascular disease in adult survivors of childhood cancer, shedding light on the relationship between diet and long-term health outcomes in this population.

6 Jul 2023

Kidney transplant recipients may benefit from new fluid therapy

A major clinical trial has found a simple change to world practice for kidney transplants could deliver real benefits for recipients and reduce their need for dialysis by 25 per cent.

6 Jul 2023

COST Connect: A platform for collaboration and progress in cancer research

Beating cancer is a major challenge for research and innovation in the coming years. By 2030, it is estimated that over 1.5 million people in the EU will succumb to cancer.

6 Jul 2023

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced updates to its flagship platform, Cyto-Mine®, enabling it to be compliant with current Good Manufacturing Practice (cGMP) regulations enforced by the US FDA.

From Fluidic Sciences and Sphere Bio 6 Jul 2023

Study offers new insights into why some CAR T-cells persist in children with leukemia

New insights explaining why some children have a longer remission than others after having cutting-edge CAR T-cell therapy for leukemia have been revealed by researchers at UCL, Great Ormond Street Hospital, and the Wellcome Sanger Institute.

6 Jul 2023

Is there an association between diabetes and breast cancer risk?

The relationship between diabetes and the risk of breast cancer.

6 Jul 2023

New therapy to mitigate fragile X syndrome may be on the horizon

An antisense therapy developed by Joel D. Richter, PhD, Sneha Shah, PhD, and Jonathan K. Watts, PhD, at UMass Chan Medical School and Elizabeth Berry-Kravis, MD, PhD, at RUSH University Medical Center, restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.

5 Jul 2023

New protein found to help melanoma evade the immune system

New research from Sanford Burnham Prebys has helped explain how melanoma evades the immune system and may guide the discovery of future therapies for the disease.

5 Jul 2023

Medical cannabis laws have no effect on opioid prescriptions, study finds

State laws allowing medical cannabis use did not reduce prescriptions for opioids or other therapies for chronic, non-cancer pain, according to a policy analysis by Weill Cornell Medicine investigators.

5 Jul 2023

Using a vaccine to boost the response of engineered T cells

Engineering T cells to destroy cancer cells has shown success in treating some types of cancer, such as leukemia and lymphoma. However, it hasn't worked as well for solid tumors.

5 Jul 2023

Study shows how glutamine can help or hinder cancer-killing activity

Scientists at St. Jude Children's Research Hospital found immune and tumor cells compete over glutamine, a major nutrient in their local environment, with significant implications for anti-cancer activity.

5 Jul 2023

Biomarker found in urine could help diagnose acute tubulointerstitial nephritis

In a study led by Johns Hopkins Medicine, in collaboration with Yale School of Medicine, researchers have identified a biomarker found via a simple urine test that can be used to diagnose acute tubulointerstitial nephritis (AIN), a medical condition that causes inflammation of the kidneys and can lead to acute kidney injury (AKI) — a sudden loss of kidney function.

5 Jul 2023

Therapy News and Research

Moderna provides an update on regulatory submissions for RSV vaccine candidate, mRNA-1345

New study shows circulating anti-insulin CD4 T cells reflect progression of anti-islet immunity

Unique plant extract mixture has potent anti-acne effects

MTB offers precision oncology strategy for advanced cancer patients

Novel approach sheds light on the interactions between SARS-CoV-2 viruses and human placenta

Triple combination therapy shows promise in long-term treatment of cystic fibrosis

Researchers show how communication networks in the tumor microenvironment promote cancer growth

Medi-Cal’s fragmented system can make moving a nightmare

Healthy diet shown to lower cardiovascular disease risk in adult childhood cancer survivors

Kidney transplant recipients may benefit from new fluid therapy

COST Connect: A platform for collaboration and progress in cancer research

Sphere Fluidics expands Cyto-Mine capabilities to meet cGMP requirements for drug manufacture workflows

Study offers new insights into why some CAR T-cells persist in children with leukemia

Is there an association between diabetes and breast cancer risk?

New therapy to mitigate fragile X syndrome may be on the horizon

New protein found to help melanoma evade the immune system

Medical cannabis laws have no effect on opioid prescriptions, study finds

Using a vaccine to boost the response of engineered T cells

Study shows how glutamine can help or hinder cancer-killing activity

Biomarker found in urine could help diagnose acute tubulointerstitial nephritis

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News